Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Operating Expenses: 2020-2024

Historic Operating Expenses for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to $221.9 million.

  • NewAmsterdam Pharma Co N.V's Operating Expenses rose 2.54% to $55.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.2 million, marking a year-over-year increase of 9.39%. This contributed to the annual value of $221.9 million for FY2024, which is 12.58% up from last year.
  • According to the latest figures from FY2024, NewAmsterdam Pharma Co N.V's Operating Expenses is $221.9 million, which was up 12.58% from $197.1 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Operating Expenses peaked at $221.9 million during FY2024, and registered a low of $6.2 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $197.1 million (2023), whereas its average is $175.1 million.
  • Data for NewAmsterdam Pharma Co N.V's Operating Expenses shows a peak YoY spiked of 464.26% (in 2021) over the last 5 years.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Operating Expenses (Yearly) stood at $6.2 million in 2020, then soared by 464.26% to $35.0 million in 2021, then soared by 203.77% to $106.3 million in 2022, then spiked by 85.46% to $197.1 million in 2023, then climbed by 12.58% to $221.9 million in 2024.